Compare Sanofi SA (SNY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vipshop Holdings Ltd - ADR — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Vipshop Holdings Ltd - ADR trades at $12.52 (market cap $6.20B). The key difference: Sanofi SA is far larger — about 16.8× Vipshop Holdings Ltd - ADR's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | VIPS | |
|---|---|---|
Market Cap | $104.06B | $6.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $20.68 |
52-Week Low | $41.33 | $12.51 |
Enterprise Value | $124.09B | $3.02B |
Dividend Yield | 5.61% | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Vipshop Holdings trades at $13.03, down 1.29% with bearish technical signals despite attractive valuation metrics including a P/E of 4.21 and P/S of 0.41. Recent earnings showed mixed results with Q2 2026 missing expectations, while revenue has declined from $112.9B in 2023 to $105.9B in 2025. The company maintains strong profitability with 9.82% net margin and robust cash flow generation.
Analyst consensus remains positive with 54% buy ratings, though near-term headwinds from consumer spending caution and competitive pressures create uncertainty. The stock's deep value proposition is balanced against growth challenges, requiring careful monitoring of Q3 2026 earnings results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
